Granted Patent
B2
US 12,209,142 · App. 17/336,276 · Granted Jan 28, 2025
SARS-CoV-2 epitope-targeted peptide immunostimulants
Inventors:
James R. Heath (Seattle, WA); Matthew Idso (Seattle, WA); Alexander J. Winton (Adelphi, MD); Matthew B. Coppock (Adelphi, MD); Sanchao Liu (Adelphi, MD)
Assignees:
Institute for Systems Biology; The United States of America as Represented by The Secretary of the Army
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPIs), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPIs. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.
Claims (19)
1. An epitope-targeted immunostimulant (EPI) comprising a synthetic peptide ligand conjugated or coupled to an antibody-recruiting moiety,
wherein:
the synthetic peptide ligand has affinity for an epitope on a SARS-CoV-2 protein exposed on a surface of a target,
the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target, and
the synthetic peptide ligand comprises the amino acid sequence tGkrw (SEQ ID NO:80), tGarn (SEQ ID NO:81), GGarn (SEQ ID NO:82), ytGak (SEQ ID NO:83), ttyre (SEQ ID NO: 84), sdyre (SEQ ID NO:85), nyrne (SEQ ID NO:86), rynes (SEQ ID NO:87), yrns (SEQ ID NO: 88), vnyks (SEQ ID NO: 89), vnfth (SEQ ID NO:90), tkhyv (SEQ ID NO:91), ykhvd (SEQ ID NO: 92), wkGpa (SEQ ID NO: 93), ytprs (SEQ ID NO:94), ytpen (SEQ ID NO:95), ydrsd (SEQ ID NO:96), refev (SEQ ID NO:97), Innkl (SEQ ID NO:98), nnpdh (SEQ ID NO:99), npshf (SEQ ID NO: 100), avGfp (SEQ ID NO: 101), vtatp (SEQ ID NO: 102), Gaavp (SEQ ID NO: 103), Gtavp (SEQ ID NO: 104), nsavp (SEQ ID NO: 105), GIGId (SEQ ID NO: 106), andkd (SEQ ID NO: 107), dpvtd (SEQ ID NO: 108), drlph (SEQ ID NO: 109), pwvdw (SEQ ID NO: 110), yylyw (SEQ ID NO:111), Gvww (SEQ ID NO:112), hwGpa (SEQ ID NO: 113), svGpk (SEQ ID NO: 114), srlGI (SEQ ID NO: 115), nylvv (SEQ ID NO: 116), wtkvv (SEQ ID NO: 117), plnvl (SEQ ID NO: 118), llsvf (SEQ ID NO: 119), Gltvf (SEQ ID NO: 120), Glysh (SEQ ID NO: 121), Gnwhw (SEQ ID NO: 122), Gkwvk (SEQ ID NO: 123), Irftf (SEQ ID NO: 124), lrfch (SEQ ID NO: 125), veptv (SEQ ID NO: 126), phpts (SEQ ID NO: 127), hrpwl (SEQ ID NO: 128), vwyGe (SEQ ID NO: 129), affdd (SEQ ID NO: 130), eyeGt (SEQ ID NO:131), andap (SEQ ID NO:132), ytnhp (SEQ ID NO: 133), tsGkn (SEQ ID NO: 134), tnehs (SEQ ID NO:135), skehs (SEQ ID NO: 136), nvsth (SEQ ID NO:137), ntrvk (SEQ ID NO: 138), Gttst (SEQ ID NO: 139), Ghnpn (SEQ ID NO: 140), tkGnl (SEQ ID NO: 141), lplrs (SEQ ID NO: 142), wlsdk (SEQ ID NO: 143), nlfda (SEQ ID NO: 144), kdlvw (SEQ ID NO: 145), akpkf (SEQ ID NO: 146), dpafa (SEQ ID NO: 147), skevd (SEQ ID NO: 148), edlvk (SEQ ID NO: 149), aakrG (SEQ ID NO:150), tsthG (SEQ ID NO: 151), senfd (SEQ ID NO: 152), eprnn (SEQ ID NO: 153), avtr (SEQ ID NO:154), dynGp (SEQ ID NO: 155), dyGvd (SEQ ID NO: 156), skdfd (SEQ ID NO: 157), fdtta (SEQ ID NO: 158), ykdld (SEQ ID NO: 159), nkvyG (SEQ ID NO: 160), kdkdw (SEQ ID NO:161), nekew (SEQ ID NO: 162), srkew (SEQ ID NO: 163), ywkde (SEQ ID NO: 164), lykkd (SEQ ID NO: 165), vwhkd (SEQ ID NO: 166), dkwdk (SEQ ID NO: 167), hyndk (SEQ ID NO: 168), hwnkd (SEQ ID NO: 169), kywkd (SEQ ID NO:170), hfwkd (SEQ ID NO: 171), kynkd (SEQ ID NO: 172), eneth (SEQ ID NO: 174), ddeks (SEQ ID NO: 175), efekd (SEQ ID NO: 176), sGnkd (SEQ ID NO: 177), ekkav (SEQ ID NO: 178), ekflt (SEQ ID NO:179), thrdt (SEQ ID NO: 180), ealpp (SEQ ID NO: 181), raavG (SEQ ID NO: 182), hvads (SEQ ID NO: 183), hleGt (SEQ ID NO: 184), kdpfs (SEQ ID NO: 185), rptwk (SEQ ID NO:186), avstv (SEQ ID NO: 187), yGnfw (SEQ ID NO:188), wnllG (SEQ ID NO: 189), wahGk (SEQ ID NO: 190), spGhG (SEQ ID NO: 191), wvGkp (SEQ ID NO: 192), yeeew (SEQ ID NO: 193), aayy (SEQ ID NO:194), aalwdsattl (SEQ ID NO: 195), flttt (SEQ ID NO: 196), dlfrd (SEQ ID NO: 197), eprrn (SEQ ID NO: 198), tkded (SEQ ID NO: 199), pvwkd (SEQ ID NO:200), wGthw (SEQ ID NO:201), yahnw (SEQ ID NO:202), Gekyh (SEQ ID NO:203), hekwy (SEQ ID NO:204), lvryt (SEQ ID NO: 205), hkdyp (SEQ ID NO:206), kpfGp (SEQ ID NO:207), rwwna (SEQ ID NO:208), trtp (SEQ ID NO:209), kkwGs (SEQ ID NO:210), hhGld (SEQ ID NO:211), vyeGt (SEQ ID NO:212), aGfpv (SEQ ID NO:213), ppwkd (SEQ ID NO:214), or rrkhf (SEQ ID NO:215).
2. The EPI of claim 1 , wherein the synthetic peptide ligand is cyclic.
3. The EPI of claim 1 , wherein the synthetic peptide ligand comprises a 1,4-substituted-1,2,3-triazole residue (Tz4) or a 1,5-substituted-1,2,3-triazole residue (Tz5).
4. The EPI of claim 3 , wherein the synthetic peptide ligand comprises a 1,4-substituted-1,2,3-triazole residue (Tz4).
5. The EPI of claim 3 , wherein the synthetic peptide ligand comprises a 1,5-substituted-1,2,3-triazole residue (Tz5).
6. The EPI of claim 1 , wherein the synthetic peptide ligand was identified by non-catalyzed in situ click chemistry screening of a combinatorial peptide library.
7. The EPI of claim 1 , wherein the SARS-CoV-2 protein is a SARS-CoV-2 spike protein.
8. The EPI of claim 7 , wherein the epitope has the amino acid sequence YGFQPTNGVGYQ (SEQ ID NO:72), CNGVEGENCYGPLQS (SEQ ID NO:73), SPDVDLGDISGINA (SEQ ID NO:74), SCVIRGDEVRQCAPG (SEQ ID NO:75), YGVSPTKLNDLCFTNV (SEQ ID NO:76), TNLCPFGEVENAT (SEQ ID NO:77), TESNKKFLPFQQFGRDIA (SEQ ID NO:78), or GQTGKIADYNYKL (SEQ ID NO:79).
9. The EPI of claim 1 , wherein the antibody-recruiting moiety comprises an epitope recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell.
10. The EPI of claim 9 , wherein the epitope recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell is an immunogen endogenously recognized by a mammalian immune system.
11. The EPI of claim 9 , wherein the epitope recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell is an immunogen endogenously recognized by a human immune system.
12. The EPI of claim 9 , wherein the epitope recognized by an antibody that mediates recognition and phagocytosis of the target by an immune cell is 2,4-dinitrophenyl (DNP), alpha-galactose, galactose(alpha1-3)galactose, beta-lactam, 1,3-diketone, avidin, fluorescein, fluorescein-DNP, or nitrophenol.
13. The EPI of claim 1 , wherein the synthetic peptide ligand is comprised in a multi-ligand, wherein the multi-ligand further comprises a second ligand covalently linked to the synthetic peptide ligand, wherein the second ligand has affinity for a second epitope on the SARS-CoV-2 protein exposed on a surface of the target, and wherein the multi-ligand can simultaneously bind to the epitope and to the second epitope on the SARS-CoV-2 protein.
14. A pharmaceutical composition comprising the EPI of claim 1 and a pharmaceutically acceptable carrier.
15. A method of stimulating an immune reaction to a SARS-COV-2 virus in a subject, the method comprising administering the pharmaceutical composition of claim 14 to the subject, wherein the SARS-CoV-2 virus in the subject is the taregt of the EPI.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 26, 2023
From: HEATH, JAMES R.; IDSO, MATTHEW
To: INSTITUTE FOR SYSTEMS BIOLOGY
Reel/Frame 062513/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 2, 2021
From: WINTON, ALEXANDER J.; COPPOCK, MATTHEW B.; LIU, SANCHAO
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 057372/0097 →
Continuity (2)
Provisional Application
63032522
· May 29, 2020
References Cited (244)
US 4899755A
· Lauffer
· 1990
[cited by applicant]
US 5474756A
· Tweedle
· 1995
[cited by applicant]
US 5547668A
· Kranz
· 1996
[cited by applicant]
US 5846519A
· Tweedle
· 1998
[cited by applicant]
US 6143274A
· Tweedle
· 2000
[cited by applicant]
US 6566088B1
· McKnight
· 2003
[cited by applicant]
US 8710180B2
· Pitram
· 2014
[cited by applicant]
US 8841083B2
· Heath
· 2014
[cited by applicant]
US 8906830B2
· Agnew
· 2014
[cited by applicant]
US 9188584B2
· Agnew
· 2015
[cited by applicant]
US 9221889B2
· Pitram
· 2015
[cited by applicant]
US 9239332B2
· Heath
· 2016
[cited by applicant]
US 9913875B2
· Farrow
· 2018
[cited by applicant]
US 20060153839A1
· Mohamed
· 2006
[cited by applicant]
US 20110177109A1
· Smith, III
· 2011
[cited by applicant]
US 20120252071A1
· Greif
· 2012
[cited by applicant]
US 20150344523A1
· Deyle
· 2015
[cited by applicant]
US 20200407712A1
· Boyd
· 2020
[cited by applicant]
EP 2719706
· 2014
[cited by applicant]
WO 1986006605
· 1986
[cited by applicant]
WO 1991003200
· 1991
[cited by applicant]
WO 1995028179
· 1995
[cited by applicant]
WO 1995028967
· 1995
[cited by applicant]
WO 1996023526
· 1996
[cited by applicant]
WO 1997036619
· 1997
[cited by applicant]
WO 1998018496
· 1998
[cited by applicant]
WO 1998018497
· 1998
[cited by applicant]
WO 1998046612
· 1998
[cited by applicant]
WO 1999017809
· 1999
[cited by applicant]
WO 9921576
· 1999
[cited by applicant]
WO 02083064
· 2002
[cited by applicant]
WO 03006620
· 2003
[cited by applicant]
WO 2005113762
· 2005
[cited by applicant]
WO 2007050963
· 2007
[cited by applicant]
WO 2009051555
· 2009
[cited by applicant]
WO 2009105746
· 2009
[cited by applicant]
WO 2009155420
· 2009
[cited by applicant]
WO 2010135431
· 2010
[cited by applicant]
WO 2011057347
· 2011
[cited by applicant]
WO 2012106651
· 2012
[cited by applicant]
WO 2012106671
· 2012
[cited by applicant]
WO 2013009869
· 2013
[cited by applicant]
WO 2013033561
· 2013
[cited by applicant]
WO 2013034982
· 2013
[cited by applicant]
WO 2013074907
· 2013
[cited by applicant]
WO 2014056813
· 2014
[cited by applicant]
WO 2014205317
· 2014
[cited by applicant]
WO 2017011769
· 2017
[cited by applicant]
WO 2017176769
· 2017
[cited by applicant]
WO 2018064597
· 2018
[cited by applicant]
WO 2018111580
· 2018
[cited by applicant]
WO 2018170096
· 2018
[cited by applicant]
WO 2018200551
· 2018
[cited by applicant]
WO 2020127227
· 2020
[cited by applicant]
Almehdi et al. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection. Aug. 2, 2021, vol. 49, pp. 855-876. (Year: 2021).
[cited by examiner]
He et al. Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein. Journal of Medical Virology. 2021, vol. 93, pp. 2115-2131. (Year: 2021).
[cited by examiner]
Yang et al. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nature Reviews. Nov. 2021, vol. 19, pp. 685-700. (Year: 2021).
[cited by examiner]
Agnew, et al., “Protein-Catalyzed Capture Agents”, Chemical Reviews, 119(17):9950-9970 (2019).
[cited by applicant]
Agnew, et al., “Iterative In Situ Click Chemistry Creates Antibody-like Protein-Capture Agents”, Angew. Chem. Int. Ed. Engl., 48(27):4944-4948 (2009).
[cited by applicant]
Albertí, et al., “C1q Binding and Activation of the Complement Classical Pathway by Klebsiella Pneumoniae Outer Membrane Proteins”, Infect. Immun., 61(3):852-860 (1993).
[cited by applicant]
Alcántar-Curiel, et al., “Association of Antibiotic Resistance, Cell Adherence, and Biofilm Production with the Endemicity of Nosocomial Klebsiella pneumoniae”, Biomed. Res. Int., (2018).
[cited by applicant]
Alcántar-Curiel, et al., “Multi-functional Analysis of Klebsiella pneumoniae fimbrial types in adherence and biofilm formation”, Virulence, 5594:129-38 (2013).
[cited by applicant]
Alexander, et al., “Intracranial black-blood MR angiography with high-resolution 3D fast spin echo”, Magn. Reson. Med., 40:298-310 (1998).
[cited by applicant]
Altschul, et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res., 25(17):3389-402 (1997).
[cited by applicant]
Arrieta-Ortiz, et al., “An experimentally supported model of the Bacillus subtilis global transcriptional regulatory network”, Mol. Syst. Biol., 11(839):1-17 (2015).
[cited by applicant]
Artali, et al., “A molecular dynamics study of human serum albumin binding sites”, II Farmaco, 60:485-495 (2005).
[cited by applicant]
Barnes, et al., “Smartphone-based pathogen diagnosis in urinary sepsis patients”, EBioMedicine, 36:73-82 (2018).
[cited by applicant]
Barrett, et al., “NCBI GEO: archive for functional genomics data sets—update”, Nucleic Acids. Res., 41: D991-5 (2013).
[cited by applicant]
Berglund, et al., “The epitope space of the human proteome”, Protein Sci., 17:606-13 (2008).
[cited by applicant]
Berry, et al., “Renal Sodium Gradient Orchestrates a Dynamic Antibacterial Defense Zone”, Cell, 170(5):860-3 (2017).
[cited by applicant]
Bertozzi, et al., “A Receptor-Mediated Immune Response Using Synthetic Glycoconjugates”, J Am Chem Soc., 114(14):5543-6 (1992).
[cited by applicant]
Bianchi, et al., “Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates”, PNAS, 107(23): 10655-10660 (2010).
[cited by applicant]
Blumer, et al., “Regulation of type 1 fimbriae synthesis and biofilm formation by the transcriptional regulator LrhA of
[cited by applicant]
Boersma, “Gaining knowledge of single carbon chains”, Theory of condensed matter, Radboud Univ. Nijmegen, 18 pages (2011).
[cited by applicant]
Borges, et al., “Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies”, Biologicals, 36:105-110 (2008).
[cited by applicant]
Brinkworth, et al., “Identification of Outer Membrane and Exoproteins of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella pneumoniae”, PLoS One, 10: e0123219 (2015).
[cited by applicant]
Brown, et al., “Antibacterial drug discovery in the resistance era”, Nature, 529:336-43 (2016).
[cited by applicant]
Bunck, et al., “Modulating the Folding Landscape of Superoxide Dismutase 1 with Targeted Molecular Binders”, Agnew Chemie, 130:6320-3 (2018).
[cited by applicant]
Bush, et al., “Tackling antibiotic resistance”, Nat. Rev. Microbiol., 9(12):894-6 (2011).
[cited by applicant]
Cahill, et al., “Klebsiella pneumoniae O antigen loss alters the outer membrane protein composition and the selective packaging of proteins into secreted outer membrane vesicles”, Microbiol Res., 180:1-10 (2015).
[cited by applicant]
Centers for Disease Control and Prevention. “Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA.”, retrieved onl…
[cited by applicant]
Chan, et al., “Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy”, Scientific Reports, 6:35247, 13 pages (2016).
[cited by applicant]
Chattopadhyay, et al., “Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers”, Cytometry Part A, 73(11): 1001-…
[cited by applicant]
Chauhan, et al. “The Taming of the Cell Penetrating Domain of the HIV Tat: Myths and Realities”, J. Control Release, 117(2): 148-162 (2007).
[cited by applicant]
Chen, et al., “Fusion protein linkers: property, design and functionality”, Adv. Drug Deliv. Rev., 65(10): 1357-1369 (2013).
[cited by applicant]
Chen, et al., “Structural and Mechanical Properties of Klebsiella pneumoniae Type 3 Fimbriae”, J. Bacteriol., 193(7):1718-25 (2011).
[cited by applicant]
Cheong, et al., “A patent review of IDO1 inhibitors for cancer”, Expert Opinion on Therapeutic Patents, 28(4):317-330 (2018).
[cited by applicant]
Chirkin, et al., “Antifungal Agents Hot Paper Neutralization of Pathogenic Fungi with Small-Molecule Immunotherapeutics”, Angew. Chemie. Int. Ed., 56:13036-40 (2017).
[cited by applicant]
Choksi, et al., “A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model”, Biology Of Blood And Marrow Transplantation,…
[cited by applicant]
Claverie, “Information enhancement methods for large scale sequence analysis”, Comput. Chem., 17:191-201 (1993).
[cited by applicant]
Cohen, et al., Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era., Science, 257(5073):1050-1055 (1997).
[cited by applicant]
Coppock, et al., “Peptide-based protein capture agents with high affinity, selectivity, and stability as antibody replacements in biodetection assays”, Proc. of SPIE, 9107:910711-1 (2014).
[cited by applicant]
Coppock, et al., “Protein Catalyzed Capture Agents with Tailored Performance for in Vitro and in Vivo Applications”, Pept. Sci., 108 (2): e22934, 13 pages (2016).
[cited by applicant]
Cowles, et al., “The free and bound forms of Lpp occupy distinct subcellular locations in
[cited by applicant]
Czaplewski, et al., “Alternatives to antibiotics—a pipeline portfolio review”, Lancet Infect. Dis., 16(2):239-51 (2016).
[cited by applicant]
Das, et al., “A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands”, Angewandte Chemie International Edition, 54(45):13219-13224 (2015).
[cited by applicant]
Davies, et al., “Origins and Evolution of Antibiotic Resistance”, Microbiol. And Mol. Biol. Rev., 74(3):417-433 (2010).
[cited by applicant]
Deleo, et al., “Molecular Dissection of the Evolution of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella Pneumoniae”, PNAS, 111 (13):4988-4993 (2014).
[cited by applicant]
Dieck, et al., “Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation”, Cell & Biology, 21:357-368 (2014).
[cited by applicant]
Digiandomenico, et al., “Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening”, J. Exp. Med., 209(7):1273-87 (2012).
[cited by applicant]
Dotiwala, et al., “Granzyme B Disrupts Central Metabolism and Protein Synthesis in Bacteria to Promote an Immune Cell Death Program”, Cell, 171(5):1125-37 (2017).
[cited by applicant]
Edelman, et al., “Extracranial carotid arteries: evaluation with “black blood” MR angiography”, Radiology, 177:45-50 (1990).
[cited by applicant]
Eiber, et al., “Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy”, The Journal Of Nuclear Medicine, 58(Supplement 2):67S-76S (2017).
[cited by applicant]
Fair, et al., “Antibiotics and Bacterial Resistance in the 21st Century”, Perspect. in Medicin. Chem., 6:25-64 (2014).
[cited by applicant]
Farrow, et al., “Epitope Targeting of Tertiary Protein Structure Enables Target-Guided Synthesis of a Potent In-Cell Inhibitor of Botulinum Neurotoxin”, Angew Chem Int Ed Engl., 54(24): 7114-7119 (2015).
[cited by applicant]
Feigman, et al., “Synthetic Immunotherapeutics against Gram-negative Pathogens Article Synthetic Immunotherapeutics against Gram-negative Pathogens”, Cell Chem. Biol., 25(10):1185-1194 (2018).
[cited by applicant]
Ferguson, et al., “Crystal Structure of the Antibiotic Albomycin in Complex with the Outer Membrane Transporter FhuA”, Protein Sci., 9:956-63 (2000).
[cited by applicant]
Fisher, et al., “Trivalent Gd-DOTA reagents for modification of proteins”, RSC Adv., 5: 96194-96200 (2015).
[cited by applicant]
Fitzer-Attas, et al., “Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the Variable Domain receptors: Optimal Design for T Call Activation”, J. Immunol., 160(1):145-154 (1998).
[cited by applicant]
Fura, et al., “D-Amino Acid Mediated Recruitment of Endogenous Antibodies to Bacterial Surfaces”, ACS Chem. Biol., 9(7):1480-9 (2014).
[cited by applicant]
Fura, et al., “Dipeptide-Based Metabolic Labeling of Bacterial Cells for Endogenous Antibody Recruitment”, ACS Infect. Dis., 2(4):302-309 (2016).
[cited by applicant]
Gao, et al., “Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2”, Nature, 387:630-4 (1997).
[cited by applicant]
Gen Bank: AAH25715.1, “CD8a molecule [Homo sapiens]” retrieved from the internet Jun. 17, 2022.
[cited by applicant]
Gerlach, et al., “Molecular characterization of the type 3 (MR/K) fimbriae of Klebsiella pneumoniae”, J. Bacteriol., 170(8):3547-53 (1988).
[cited by applicant]
Giandomenico, et al., “A multifunctional bispecific antibody protects against Pseudomonas aeruginosa”, Sci. Transl. Med., 6:262ra155, 12 pages (2014).
[cited by applicant]
Gold, et al., “Antimicrobial-Drug Resistance”, N. Engl. J. Med., 335:1445-1453 (1996).
[cited by applicant]
Goodrich, et al., “A quantitative study of ramped radio frequency, magnetization transfer, and slab thickness in three-dimensional time-of-flight magnetic resonance angiography in a patient population”, Invest. Radia., …
[cited by applicant]
Guilhen, et al., “Transcriptional profiling of Klebsiella pneumoniae defines signatures for planktonic, sessile and biofilm-dispersed cells”, BMC Genomics, 17:237, 15 pages (2016).
[cited by applicant]
Hancock, et al., “Modulating Immunity as a Therapy for 10 Bacterial Infections”, Nat. Rev. Microbio., 10(4):243-54 (2012).
[cited by applicant]
Handl, et al., “Hitting multiple targets with multimeric ligands”, Expert Opin. Ther. Targets, 8(6):565-586 (2004).
[cited by applicant]
Hill, et al., “Constraining Cyclic Peptides To Mimic Protein Structure Motifs”, Angewandte Chemie, 53(48):13020-13041 (2014).
[cited by applicant]
Hirai, et al., “MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo”, Molecular Cancer Therapeutics, 9(7): 1956-1967 (20…
[cited by applicant]
Högberg, et al., “The Global Need for Effective Antibiotics: Challenges and Recent Advances”, Trends Pharmacol. Sci., 31(11):509-515 (2010).
[cited by applicant]
Holt, et al., “Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health”, PNAS, 112(27): E3574-81 (2015).
[cited by applicant]
Hsieh, et al., “Klebsiella pneumoniae Peptidoglycan-Associated Lipoprotein and Murein Lipoprotein Contribute to Serum Resistance, Antiphagocytosis, and Proinflammatory Cytokine Stimulation”, J. Infect. Dis., 208(10):158…
[cited by applicant]
Huang, et al., “Capsule Deletion via a λ-Red Knockout System Perturbs Biofilm Formation and Fimbriae Expression in Klebsiella Pneumoniae MGH 78578”, BMC Res. Notes, 7:13, 8 pages (2014).
[cited by applicant]
Hudson, et al, “Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes”, Scientific Reports, 2(706):1-9 (2012).
[cited by applicant]
Humphries, et al., “Case Report Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and Colistin”, J. Med. Microbiol., 59(pt. 11):1383-6 (201…
[cited by applicant]
Humphries, et al., “Salmonella enterica Serotype Typhimurium Fimbrial Proteins Serve as Antigens during Infection of Mice”, Infect. Immun., 73(9):5329-38 (2005).
[cited by applicant]
Jespersen, et al., “BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes”, Nucleic Acids Res., 45: W24-9 (2017).
[cited by applicant]
Josan, et al., “Cell-specific targeting by heterobivalent ligands”, Bioconjug Chem., 22(7): 1270-1278 (2011).
[cited by applicant]
Karjalaninen, et al., “Concentrations of three hapten-binding immunoglobulins in pooled normal human serum”, Eur. J. Immunol., 6(2):88-93 (1976).
[cited by applicant]
Kavvas, et al., “Machine Learning and Structural Analysis of
[cited by applicant]
Klausen, et al., “NetSurfP-2.0: improved prediction of protein structural features by integrated deep learning”, BioRxiv, 311209, 14 pages (2018).
[cited by applicant]
Krishnamurthy, et al., “Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide”, Biomaterials, 27:3663-74 (2006).
[cited by applicant]
Kurupati, et al., “Identification of Vaccine Candidate Antigens of an ESBL Producing Klebsiella Pneumoniae Clinical Strain by Immunoproteome Analysis”, Proteomics, 6:836-844 (2006).
[cited by applicant]
Lai, et al., “Epitope-Targeted Macrocyclic Peptide Ligand with Picomolar Cooperative Binding to Interleukin-17F”, Chemistry, 24(15):3760-3767 (2018).
[cited by applicant]
Lee, et al., “Klebsiella Pneumoniae Secretes Outer Membrane Vesicles that Induce the Innate Immune Response”, FEBS Microbiol Lett., 331(1):17-24 (2012).
[cited by applicant]
Lee, et al., “Network Integrative Genomic and Transcriptomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae Strains Identifies Genes for Antibiotic Resistance and Virulence”, mSystems, 4: e00202-19 (2019).
[cited by applicant]
Lee, et al., “Rapid Microwave-assisted CNBr Cleavage of Bead-bound Peptides”, J. Comb. Chem., 10(6):807-9 (2008).
[cited by applicant]
Li, et al., “Identification of the CD8 DE loop as a surface functional epitope. Implications for major histocompatibility complex class I binding and CD8 inhibitor design”, Journal Of Biological Chemistry, 273(26): 1644…
[cited by applicant]
Lin, et al., “Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway”, Journal of Virology, 85(17): 9114-9126 (2011).
[cited by applicant]
Lin, et al., “Phosphoproteomics of Klebsiella Pneumoniae NTUH-K2044 Reveals a Tight Link between Tyrosine Phosphorylation and Virulence”, Mol. Cell. Proteomics, 8(12):2613-2623 (2009).
[cited by applicant]
Lindlsey, et al., “The P13K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors”, Current Cancer Drug Targets, 8: 7-18 (2008).
[cited by applicant]
Liu, et al., “Study on Mechanisms of Colonization of Nitrogen-Fixing PGPB, Klebsiella pneumoniae NG14 on the Root Surface of Rice and the Formation of Biofilm”, Curr. Microbiol., 62(4):1113-22 (2011).
[cited by applicant]
Lorenz, et al., “Functional Antibodies Targeting IsaA of
[cited by applicant]
Lu, et al., “Beyond binding: antibody effector functions in infectious diseases”, Nat. Rev. Immunol., 18(1):46-61 (2019).
[cited by applicant]
Lu, et al., “Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential”, Mol. Pharm., 4(5):2432-43 (2007).
[cited by applicant]
Ma, et al., “A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A”, Toxicon, 47(8):901-908 (2006).
[cited by applicant]
Mabry, et al., “Engineering of stable bispecific antibodies targeting IL-17 A and IL-23”, Protein Engineering, Design & Selection, 23(3):115-127 (2010).
[cited by applicant]
Macraild et al., “Antibody Recognition of Disordered Antigens”, Structure 24:148-157, (2016).
[cited by applicant]
Macraild et al., “Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2”, PLOS One, 13 pages (2015).
[cited by applicant]
Mádiera, et al., “The EMBL-EBI search and sequence analysis tools APIs in 2019”, Nucleic Acids Res., 47(W1):W636-W641 (2019).
[cited by applicant]
Manea, et al., “Antibody Recognition and Conformational Flexibility of a Plaque-Specific-Amyloid Epitope Modulated by Non-native Peptide Flanking Regions”, J. Med. Chem., 51(5):1150-1161 (2008).
[cited by applicant]
Marbach, et al., “Wisdom of crowds for robust gene network inference”, Nat Methods., 9(8):796-804 (2016).
[cited by applicant]
Martin, et al., “Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae”, Front Cell Infect. Microbiol., 8:4, 15 pages (2018).
[cited by applicant]
Matsuura, “Identification of conformational neutralizing epitopes on the capsid protein of canine calicivirus”, Journal of General Virology, 82:1695-1702 (2001).
[cited by applicant]
McCarthy, et al., “Allosteric Inhibitor of KRas Identified Using a Barcoded Assay Microchip Platform”, Anal Chem., 90(15):8824-30 (2018a).
[cited by applicant]
McCarthy, et al., “Phage Display of Dynamic Covalent Binding Motifs Enables Facile Development of Targeted Antibiotics”, J. Am. Chem. Soc., 140(19):6137-45 (2018b).
[cited by applicant]
McEnaney, et al., “Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease”, ACS Chem. Biol., 7(7):1139-1151 (2012).
[cited by applicant]
Melenhorst et el., “Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers”, J Immunol Methods, 338(1-2): 31-39 (2008).
[cited by applicant]
Merriam-Webster online definition of “correspond” downloaded Jun. 29, 2020 from internet, https://www.merriam-webster.com/dictionary/correspond (Year: 2020).
[cited by applicant]
Meyers and Miller, “Optimal alignments in linear space”, Comp Applic. Biol. Sci., 4(1):11-17 (1988).
[cited by applicant]
Millward, et al., “In situ click chemistry: from small molecule discovery to synthetic antibodies”, Integr. Biol (Camb)., 5(1): 87-95 (2013).
[cited by applicant]
Millward, et al., “Iterative in situ click chemistry assembles a branched capture agent and allosteric inhibitor for Akt1”, JACS, 133(45):18280-18288 (2011).
[cited by applicant]
Miossec, “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice”, RMD Open, m3(1):e000284 (2017).
[cited by applicant]
Molina-Santiago, et al., “Differential Transcriptional Response to Antibiotics by Pseudomonas Putida DOT-T1E”, Environ. Microbiol., 17(9): 3251-3262 (2015).
[cited by applicant]
Mor, et al., Mimicking the Structure of the V3 Epitope Bound to HIV-1 Neutralizing Antibodies, Biochemistry, 48(15):3288-3303 (2009).
[cited by applicant]
Muller, et al., “DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice”, The Journal Of Nuclear Medicine, 54(1):124-131 (2013).
[cited by applicant]
Muller, et al., “Folic acid conjugates for nuclear imaging of folate receptor-positive cancer”, J. Nucl. Med., 52(1): 1-4 (2011).
[cited by applicant]
Munoz-Price, et al., “Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases”, Lancet Infect. Dis., 13(9):785-96 (2013).
[cited by applicant]
Murelli, et al., “Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate Cancer”, J. Am. Chem. Soc., 131(47):17090-2 (2009).
[cited by applicant]
Nag et al., “A chemical epitope-targeting strategy for protein capture agents: the serine 474 epitope of the kinase Akt2”, Angewandte Chemie International Edition, 52:13975-13979 (2013).
[cited by applicant]
O'Shannessy, et al., “Characterization of the human folate receptor alpha via novel antibody-based probes”, Oncotarget, 2(12):1227-1243 (2011).
[cited by applicant]
Opal, “Non-Antibiotic Treatments for Bacterial Diseases in an Era of Progressive Antibiotic Resistance”, Crit. Care, 20(1):397, 3 pages (2016).
[cited by applicant]
Paczosa, et al., “Klebsiella pneumoniae: Going on the Offense with a Strong Defense”, Microbiol. Mol. Biol. Rev., 80(3):629-61 (2016).
[cited by applicant]
Pansca, et al., “Structural disorder in eukaryotes”, PLoS One, www.plosone.org Apr. 1, 2012, 7(4):e34687, 10 pages (2012).
[cited by applicant]
Pelfrene, et al., “Monoclonal antibodies as anti-infective products: a promising future?”, Clin. Microbiol. Infect., 25(1):60-4 (2019).
[cited by applicant]
Pfeilsticker, et al., “A cocktail of thermally stable, chemically synthesized capture agents for the efficient detection of anti-gp41 antibodies from human sera”, PloS One, 8(10):Article No. e76224, 5 pages (2013).
[cited by applicant]
Pitout, et al., “Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance”, Antimicrob. Agents Chemother., 59(10):5873-84 (2015).
[cited by applicant]
Robinson, et al., “Antibiotic Resistance Is the Quintessential One Health Issue”, Trans. R. Soc. Trop. Med. Hyg., 110(7): 377-380 (2016).
[cited by applicant]
Roca, et al., “The Global Threat of Antimicrobial Resistance: Science for Intervention”, New Microbes New Infect., 6(C): 22-29 (2015).
[cited by applicant]
Roope, et al., “The challenge of antimicrobial resistance: What economics can contribute”, Science, 364(6435): eaau4679, 41 pages (2019).
[cited by applicant]
Rullo, et al., “Antitumor Agents Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor”, Angew Chemie., 128(11):3706-10 (2016).
[cited by applicant]
Sabulski, et al., “Immuno-targeting of
[cited by applicant]
Saito, et al., “Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization”, Cancer Science, 105(4): 396-401 (2014).
[cited by applicant]
Saphire, et al., “Antibody-mediated protection against Ebola virus”, Nat. Immunol., 19(11):1169-78 (2018).
[cited by applicant]
Sarbassov, et al., “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex”, Science, American Association for The Advancement Of Science, 307(5712): 1098-1101 (2005).
[cited by applicant]
Sauer, et al., “Fiber assembly by the chaperone-usher pathway”, Biochem. Biophys. Acta., 1694(1-3):259-67 (2004).
[cited by applicant]
Schweinsberg, et al., “Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors”, Bioconjugate Chem., 19(12):2432-2439 (2008).
[cited by applicant]
Seo, et al., “Multiple-Omic Data Analysis of Klebsiella Pneumoniae MGH 78578 Reveals Its Transcriptional Architecture and Regulatory Features”, BMC Genomics, 13(679): 12 pages (2012).
[cited by applicant]
Shokat, et al., “Redirecting the Immune Response: Ligand-Mediated Immunogenicity”, J. Am. Chem. Soc., 113(16): 1861-1862 (1991).
[cited by applicant]
Son, et al., “New Cyclic Lipopeptides of the Iturin Class Produced by Saltern-Derived
[cited by applicant]
Sparrow, et al., “Therapeutic antibodies for infectious diseases”, Bull World Health Organ., 95(3):235-7 (2017).
[cited by applicant]
Spellberg, et al., “The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America”, Clin. Infect. Dis., 46(2):155-64 (2008).
[cited by applicant]
Subramanyam, et al., “Inhibition of Protein Kinase Akt1 by Apoptosis Signal-regulating Kinase-1 (ASK1) Is Involved in Apoptotic Inhibition of Regulatory Volume Increase”, Journal of Biological Chemistry, 285(9): 6109-61…
[cited by applicant]
Tacconelli, et al., “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis”, Lancet. Infect. Dis., 18(3):318-27 (2018).
[cited by applicant]
Tang et al., “Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells”, Asian Journal of Andrology, 11(1): 119-126 (2009).
[cited by applicant]
Tao, et al., “Expression, purification and identification of an immunogenic fragment in the ectodomain of prostate-specific membrane antigen”, Experimental And Therapeutic Medicine, 11(3):747-752 (2016).
[cited by applicant]
Thoma, et al., “Out but Not In: The Large Transmembrane Beta-Barrel Protein FhuA Unfolds but Cannot Refold via Beta-Hairpins”, Structure, 20(12):2185-90 (2012).
[cited by applicant]
Todorova, et al., “Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induces after immunization with gene-based vaccines”, Anticancer Research, 25: 4727-4732 (2005).
[cited by applicant]
Torres, et al., “A revolutionary therapeutic approach for psoriasis: bi specific biological agents”, Expert Opinion On Investigational Drugs, 25(7): 751-754 (2016).
[cited by applicant]
Tsang, et al., “NlpD links cell wall remodeling and outer membrane invagination during cytokinesis in
[cited by applicant]
Tzouvelekis, et al., “Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions”, Clin. Microbiol. Rev., 25:682-707 (2012).
[cited by applicant]
Van Laar, et al., “Sublethal Concentrations of Carbapenems Alter Cell Morphology and Genomic Expression of Klebsiella pneumoniae Biofilms”, Antimicrob. Agents. Chemother., 59(3):1707-17 (2015).
[cited by applicant]
Ventola, et al., “The Antibiotic Resistance Crisis Part 1: Causes and Threats”, Pharm. Ther., 40:277-83 (2015).
[cited by applicant]
Wang, et al., “Epitope Mapping Using Phage-Display Random Fragment Libraries”, Epitope Mapping Protocols, Methods in Molecular Biology, 524: 315-332 (2009). Abstract Only.
[cited by applicant]
Wang, et al., “Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90 Y-DOTA-EB-MCG”, Bioconjugate Chemistry, 29(7): 2309-2315 (2018).
[cited by applicant]
Wang, et al., “Anti-MrkA monoclonal antibodies reveal distinct structural and antigenic features of MrkA”, PLoS One, 12(1):e017059, 13 pages (2017).
[cited by applicant]
Wang, et al., “Combined Use of Proteomic Analysis and Enzyme Activity Assays for Metabolic Pathway Analysis of Glycerol Fermentation by Klebsiella Pneumoniae”, Biotechnol. Bioeng., 83(5):525-536 (2003).
[cited by applicant]
Wang, et al., “Target-Agnostic Identification of Functional Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit”, J. Infect. Dis., 213(11):1800-8 (2018a).
[cited by applicant]
Wargo, et al., “Pulmonary Surfactant Promotes Virulence Gene Expression and Biofilm Formation in Klebsiella Pneumoniae”, Infect. Immun., 86(7):e00135-18 (2018).
[cited by applicant]
Waterhouse, et al., “Jalview Version 2—a multiple sequence alignment editor and analysis workbench”, Bioinformatics, 25(9):1189-91 (2009).
[cited by applicant]
Watkins, et al., “Overview: Global and Local Impact of Antibiotic Resistance”, Infect. Dis. Clin. North Am., 30(2): 313-322 (2016).
[cited by applicant]
Wen, et al., “G-protein-coupled formyl peptide receptors play a dual role in neutrophil chemotaxis and bacterial phagocytosis”, Mol. Biol. Cell., 30(3):346-56 (2019).
[cited by applicant]
Wilson, et al., “Surface-Exposed Lipoproteins: An Emerging Secretion Phenomenon in Gram-Negative Bacteria”, Trends Microbiol., 24(3):198-208 (2016).
[cited by applicant]
Wise, et al., “Antimicrobial Resistance Is a Major Threat to Public Health”, Br. Med. J., 317(7159): 609-610 (1998).
[cited by applicant]
Wooldridge, et al., “Tricks with tetramers: how to get the most from multimeric peptide-MHC”, Immunology, 126:147-164 2009 (2009).
[cited by applicant]
Wootton, et al., “Statistics of local complexity in amino acid sequences and sequences databases”, Comput. Chem., 17(2):149-63 (1993).
[cited by applicant]
World Health Organization (2014), “Antimicrobial resistance: Global Report on Surveillance”, retrieved from internet < https://apps.who.int/iris/handle/10665/112642>, Jul. 21, 2022.
[cited by applicant]
Zhang, et al., “Structure and function of interleukin-17 family cytokines”, Protein & Cell, 2(1): 26-40 (2011).
[cited by applicant]
Agalave, et al., “Click chemistry: 1,2,3-triazoles as pharmacophores”, Chem. Asian J., 6: (10)2696-27018 (2011).
[cited by applicant]
BPS Bioscience: INCB024360 Analog Data Sheet (2012).
[cited by applicant]
Glaven, “Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target”, Biosensors, 2:43-56 (2012).
[cited by applicant]
Kirszbaum, et al., “The alpha-chain of murine CD8 lacks an invariant lg-like disulfide bond but contains a unique intrachain loop instead”, J. Immunol., 142(11):3931-6 (1989).
[cited by applicant]
Koonin, et al., “Sequence—Evolution—Function: Computational Approaches in Comparative Genomics”, Boston: Kluwer Academic; 2003, Chapter 2 Evolutionary Concept in Genetics and Genomics (2003).
[cited by applicant]
Mamidyala, et al., “In situ click chemistry : probing the binding landscapes of biological molecules”, Chemical Society Reviews, 39(4):1252-1261 (2010).
[cited by applicant]
Reeck, et al., “Homolgy' in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of it”, Cell, 50:667 (1987).
[cited by applicant]
Smith, et al., “Zinc Mediated Azide-Alkyne Ligation to 1,5- and 1,4,5-Substituted 1,2,3-Triazoles”, Org. Lett., 15(18):4826-4829 (2013).
[cited by applicant]
Sormanni, et al., “Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins”, PNAS, 112(32):9902-9907 (2015).
[cited by applicant]
Sormanni, etal., PNAS, 112(32):1-10, Supplemental Materials (2015).
[cited by applicant]
Testa, et al., “CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies”, Biomarker Research, 2:4 (2014).
[cited by applicant]
Wang, et al., “Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position”, J. Immunol., 183(4):2554-64 (2009).
[cited by applicant]